LM-030 / Novartis, Lifemax Healthcare - LARVOL DELTA

[VIRTUAL] Rationale and design for the Kallikrein Inhibitor in Netherton Syndrome (KINS) pivotal clinical trial (SID 2020) - "We summarize the Kallikrein Inhibitor in Netherton Syndrome (KINS) study, the first Phase 2/3, multicenter, randomized, double-blind, vehicle-controlled trial to evaluate the safety, efficacy and tolerability of a novel topical therapeutic (LM-030) in NS patients...The KINS study, targeted for initiation in the US and EU in mid-2020, will enroll over 100 patients. Additional design details will be presented in the presentation."

Clinical • Allergy • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • ELANE • KLK7

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome (clinicaltrials.gov) - P1; N=12; Completed; Sponsor: Novartis Pharmaceuticals; Trial primary completion date: Mar 2014 ->Feb 2014

Trial primary completion date • Acute Coronary Syndrome • Biosimilar • Chronic Kidney Disease • Dermatitis • Eczema • Heart Failure • Immunology